Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation р.T632I

Approximately 15% of acral and mucous melanomas carry activating mutations in KIT oncogene. There is a diversity of spectrum of KIT mutations, with some of them rendering tumors responsive to imatinib, while others being imatinib-resistant or not studied yet. Here we present an acral melanoma patient with KIT р.T632I mutation, who failed to respond to imatinib.
Case Rep Oncol 2019;12:109–112

http://bit.ly/2Wa4aI5